Welcome to our dedicated page for Armata Pharmctcl news (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmctcl stock.
Armata Pharmaceuticals develops pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. News about ARMP centers on its late clinical-stage phage pipeline, including AP-SA02 for Staphylococcus aureus bacteremia and AP-PA02 for Pseudomonas aeruginosa, FDA designations and regulatory interactions, scientific publications on phage structure, and clinical program updates.
Company updates also cover financial results, research and development spending, grant-supported program activity, credit agreement and warrant amendments with Innoviva-related entities, and board or annual-meeting governance matters. Armata describes in-house phage-specific cGMP manufacturing as part of its development model.
Armata Pharmaceuticals (NYSE: ARMP) received an End-of-Phase 2 written response from the FDA and the agency agreed that data from Armata's Phase 2a diSArm study support advancing AP-SA02 into a Phase 3 superiority study in complicated Staphylococcus aureus bacteremia. The company plans to initiate the Phase 3 study in the second half of 2026 and is addressing FDA comments on CMC, clinical design, and BLA recommendations. Armata has submitted a request for QIDP designation and highlighted Phase 2a results announced in May 2025 and presented at IDWeek 2025.
Armata Pharmaceuticals (NYSE: ARMP) received an End-of-Phase 2 written response from the FDA confirming that safety and efficacy data from its Phase 2a diSArm study support advancing IV AP-SA02 into a Phase 3 superiority study for complicated Staphylococcus aureus bacteremia. The Phase 3 trial is anticipated to initiate in the second half of 2026 and will test AP-SA02’s superiority versus standard of care, with primary endpoints at end of best available antibiotic therapy and at Day 28. The FDA provided guidance on study design, CMC, BLA expectations, and encouraged a QIDP request; Armata has submitted a QIDP request and is addressing FDA comments.
Armata Pharmaceuticals (NYSE American: ARMP) will host a KOL webinar on November 25, 2025 at 10:00am EST featuring Dr. Vance G. Fowler Jr. on complicated S. aureus bacteremia and Armata's phage therapy AP-SA02.
The company highlighted positive Phase 1b/2a diSArm results presented at IDWeek 2025 showing AP-SA02 plus best available antibiotic therapy produced a higher, earlier cure rate at Test of Cure and a 100% response without relapse at TOC and 28 days later (EOS) versus ~25% lack of response/relapse for placebo plus BAT. AP-SA02 was reported well-tolerated with efficacy against MRSA and MSSA.
Armata Pharmaceuticals (NYSE: ARMP) reported Q3 2025 results and a corporate update on November 12, 2025. Key clinical news: Phase 1b/2a AP-SA02 (IV) for complicated Staphylococcus aureus bacteremia showed higher and earlier cure at day 12 versus placebo+BAT, with a 100% response without relapse at one week and day 28 in the AP-SA02 arm versus ~25% nonresponse/relapse in placebo. AP-SA02 was well tolerated and shortened time to negative blood culture and hospital utilization. Operationally, Armata commissioned its Los Angeles cGMP facility and closed a $15.0M secured loan; unrestricted cash was $14.8M as of Sept 30, 2025.
Armata Pharmaceuticals (NYSE American: ARMP) announced formal commissioning of its new cGMP phage manufacturing facility in Los Angeles on November 10, 2025. The 56,000 sq ft site includes 10,000 sq ft of cGMP clean rooms, an automated fill-and-finish suite, quality control and R&D labs, and administrative space. The company notified the FDA that production has commenced and completed full production runs with no issues. The facility is positioned to supply high-purity multi-phage cocktails for clinical programs and to support a potential Phase 3 AP-SA02 trial planned for 2026, subject to FDA review, plus future commercial and contract manufacturing opportunities.
Armata Pharmaceuticals (NYSE American: ARMP) reported positive Phase 2a diSArm results for IV bacteriophage cocktail AP-SA02 in complicated Staphylococcus aureus bacteremia, presented at IDWeek 2025 on Oct 22, 2025. The randomized, double-blind trial enrolled 42 patients (29 AP-SA02 + BAT; 13 placebo + BAT).
Day 12 clinical response: 88% vs 58% (PI assessment, p=0.047); adjudicator assessment 83% vs 58%. Non-response/relapse at one week post-BAT and at EOS: 0% AP-SA02 vs ~25% placebo (p-values 0.017–0.025). AP-SA02 was well tolerated; no serious adverse events related to drug. Armata plans a Phase 3 superiority trial in 2026, subject to FDA feedback.
Armata Pharmaceuticals (NYSE American: ARMP) will present late-breaking Phase 2a clinical data on its Staphylococcus aureus bacteriophage cocktail AP-SA02 at IDWeek 2025 in Atlanta, GA.
The oral presentation, titled "A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus aureus Bacteremia," will be given by Dr. Loren G. Miller on Wednesday, October 22, 2025, from 10:30 AM to 11:45 AM ET in room B401-B402 during the session "Late Breaking Info That May Change Your Approach To Bacterial and Fungal Infections."
Armata Pharmaceuticals (NYSE American: ARMP) announced the publication of a research paper in the Journal of Molecular Biology detailing the structural analysis of phage Pa223, a component of their clinical candidate AP-PA02. The study provides the first structural description of a phage from the Bruynoghevirus genus using advanced cryogenic electron microscopy.
AP-PA02, a five-phage cocktail, is being developed to treat chronic respiratory infections in cystic fibrosis and non-cystic fibrosis bronchiectasis (NCFB) patients. The therapeutic has demonstrated promising results in two Phase 2 clinical trials - SWARM-P.a. and Tailwind. The structural insights gained from this research may inform future development of phage-based therapeutics.
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotech company developing bacteriophage therapeutics, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Deborah Birx, M.D. will deliver a corporate presentation on September 10, 2025, from 1:30-2:00 PM ET in New York. The company specializes in developing treatments for antibiotic-resistant and difficult-to-treat bacterial infections.
Armata Pharmaceuticals (NYSE American: ARMP) announced significant Q2 2025 developments, including a $15 million secured credit agreement with Innoviva and positive topline results from their Phase 1b/2a diSArm trial for AP-SA02, their lead S. aureus therapeutic candidate.
The company reported Q2 2025 financial results with grant revenue of $2.2 million, R&D expenses of $6.4 million, and cash position of $4.3 million. Additionally, Armata received $4.65 million in non-dilutive funding from the U.S. Department of Defense.
The diSArm trial met all primary endpoints, demonstrating improved clinical outcomes compared to standard antibiotic therapy with no treatment-related serious adverse events. Armata plans to initiate a Phase 3 pivotal trial in 2026 following an FDA end-of-Phase 2 meeting later this year.